| Fiscal period | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Period End Date | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 |
|---|
| Net Sales | 35,355.00 | 32,184.00 | 32,136.00 | 32,765.00 | 31,657.00 | 30,109.00 | 30,274.00 | 31,821.00 | 30,871.00 | 29,904.00 |
| Total Revenues | 35,355.00 | 32,184.00 | 32,136.00 | 32,765.00 | 31,657.00 | 30,109.00 | 30,274.00 | 31,821.00 | 30,871.00 | 29,904.00 |
| Cost of sales | 18,795.00 | 16,605.00 | 17,136.00 | 16,682.00 | 16,055.00 | 15,118.00 | 15,383.00 | 16,447.00 | 16,106.00 | 15,685.00 |
| Gross Profit | 16,560.00 | 15,579.00 | 15,000.00 | 16,083.00 | 15,602.00 | 14,991.00 | 14,891.00 | 15,374.00 | 14,765.00 | 14,219.00 |
| Research, development and related expenses | 1,994.00 | 1,878.00 | 1,911.00 | 1,821.00 | 1,870.00 | 1,764.00 | 1,763.00 | 1,770.00 | 1,715.00 | 1,634.00 |
| Selling, general and administrative expenses | 7,197.00 | 6,929.00 | 7,029.00 | 7,602.00 | 6,626.00 | 6,311.00 | 6,229.00 | 6,469.00 | 6,384.00 | 6,102.00 |
| Other (expense) income | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Gain on sale of pharmaceuticals business | -- | 389.00 | 114.00 | 547.00 | 586.00 | 111.00 | 47.00 | -- | -- | -- |
| Total Operating Expenses | 27,986.00 | 25,023.00 | 25,962.00 | 25,558.00 | 23,965.00 | 23,082.00 | 23,328.00 | 24,686.00 | 24,205.00 | 23,421.00 |
| Operating Income (Loss) | 7,369.00 | 7,161.00 | 6,174.00 | 7,207.00 | 7,692.00 | 7,027.00 | 6,946.00 | 7,135.00 | 6,666.00 | 6,483.00 |
| Interest expense | -- | -- | -- | -- | -- | -- | -- | 142.00 | 145.00 | 171.00 |
| Interest income | -- | -- | -- | -- | -- | -- | -- | 33.00 | 41.00 | 39.00 |
| Other expense (income), net | (165.00) | (366.00) | (531.00) | (207.00) | (144.00) | (26.00) | (123.00) | -- | -- | -- |
| Pre-Tax Income: United States | 3,716.00 | 3,795.00 | 2,954.00 | 3,487.00 | 4,149.00 | 4,366.00 | -- | 3,815.00 | 3,194.00 | 2,902.00 |
| Pre-Tax Income - International | 3,488.00 | 3,000.00 | 2,689.00 | 3,513.00 | 3,399.00 | 2,687.00 | -- | 3,211.00 | 3,368.00 | 3,449.00 |
| Income before income taxes, minority interest and cumulative effect of accounting | 7,204.00 | 6,795.00 | 5,643.00 | 7,000.00 | 7,548.00 | 7,053.00 | 6,823.00 | 7,026.00 | 6,562.00 | 6,351.00 |
| Current : Federal | 756.00 | 720.00 | 534.00 | 698.00 | 1,022.00 | 1,192.00 | -- | 1,103.00 | 948.00 | 743.00 |
| Current : State | 104.00 | 123.00 | 59.00 | 109.00 | 59.00 | 75.00 | -- | 108.00 | 91.00 | 75.00 |
| Provision for income taxes | 1,285.00 | 1,337.00 | 1,114.00 | 1,637.00 | 2,679.00 | 1,995.00 | 1,982.00 | 2,028.00 | 1,841.00 | 1,840.00 |
| Deferred: Federal | (219.00) | (44.00) | (43.00) | (38.00) | 162.00 | -- | -- | (171.00) | (123.00) | (3.00) |
| Deferred: State | (25.00) | (17.00) | (28.00) | (17.00) | 15.00 | -- | -- | (9.00) | (2.00) | 10.00 |
| Currently payable: International | 597.00 | 632.00 | 673.00 | 763.00 | 722.00 | 733.00 | -- | 1,008.00 | 901.00 | 918.00 |
| Deferred: International | 72.00 | (77.00) | (81.00) | (54.00) | 76.00 | -- | -- | (11.00) | 26.00 | 97.00 |
| Minority interest | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Income (loss) from unconsolidated subsidiaries, net of taxes | 10.00 | (5.00) | -- | -- | -- | -- | -- | -- | -- | -- |
| INCOME BEFORE CUMULATIVE EFFECT OF ACCOUNTING CHANGE | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cumulative effect of accounting change | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net income including noncontrolling interest | 5,929.00 | 5,453.00 | 4,529.00 | 5,363.00 | 4,869.00 | 5,058.00 | 4,841.00 | 4,998.00 | 4,721.00 | 4,511.00 |
| Less- Net income attributable to noncontrolling interest | 8.00 | 4.00 | 12.00 | 14.00 | 11.00 | 8.00 | 8.00 | 42.00 | 62.00 | 67.00 |
| Net Income (Loss) Available to Common Shareholders | 5,921.00 | 5,449.00 | 4,517.00 | 5,349.00 | 4,858.00 | 5,050.00 | 4,833.00 | 4,956.00 | 4,659.00 | 4,444.00 |
| Basic: Income before cumulative effect of accounting change | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Basic: Cumulative effect of accounting change | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Earnings per share - Basic | 10.23 | 9.43 | 7.83 | 9.09 | 8.13 | 8.35 | 7.72 | 7.63 | 6.83 | 6.40 |
| Diluted: Income before cumulative effect of accounting change | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Diluted: Cumulative effect of accounting change | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Earnings per share - Diluted | 10.12 | 9.36 | 7.72 | 8.89 | 7.93 | 8.16 | 7.58 | 7.49 | 6.72 | 6.32 |
| Weighted average common shares outstanding - Basic | 579.00 | 577.60 | 577.00 | 588.50 | 597.50 | 604.70 | 625.60 | 649.20 | 681.90 | 693.90 |
| Weighted average common shares outstanding - Diluted | 585.30 | 582.20 | 585.10 | 602.00 | 612.70 | 618.70 | 637.20 | 662.00 | 693.60 | 703.30 |